In following studies demonstrating the proficient effect of PARP inhibition in breast, prostate and pancreatic cancers, PARP1 emerged as a new target for platinum-sensitive tumors, thereby helping personalized therapy and HRD testing in routine diagnostics to receive increased relevance and importance. This evidence concerns the gene PARP1 and pancreatic neoplasm.